The Manufacturers Life Insurance Company lifted its stake in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 18.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 72,563 shares of the company's stock after acquiring an additional 11,205 shares during the quarter. The Manufacturers Life Insurance Company owned approximately 0.12% of Oruka Therapeutics worth $3,559,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Viking Global Investors LP acquired a new stake in Oruka Therapeutics in the third quarter valued at approximately $51,280,000. Deep Track Capital LP lifted its holdings in shares of Oruka Therapeutics by 38.4% in the 3rd quarter. Deep Track Capital LP now owns 2,654,781 shares of the company's stock worth $51,051,000 after purchasing an additional 735,983 shares in the last quarter. Vanguard Group Inc. grew its position in Oruka Therapeutics by 38.1% in the 4th quarter. Vanguard Group Inc. now owns 2,453,530 shares of the company's stock valued at $74,366,000 after purchasing an additional 676,865 shares during the period. RTW Investments LP increased its stake in Oruka Therapeutics by 5.8% during the 4th quarter. RTW Investments LP now owns 2,058,148 shares of the company's stock valued at $62,382,000 after purchasing an additional 112,499 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP bought a new stake in Oruka Therapeutics during the 4th quarter valued at $51,840,000. Institutional investors and hedge funds own 56.44% of the company's stock.
Insider Transactions at Oruka Therapeutics
In other Oruka Therapeutics news, CEO Lawrence Otto Klein sold 1,729 shares of the business's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $69.69, for a total value of $120,494.01. Following the sale, the chief executive officer directly owned 925,580 shares in the company, valued at $64,503,670.20. The trade was a 0.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Carl Dambkowski sold 105,000 shares of Oruka Therapeutics stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $58.97, for a total value of $6,191,850.00. Following the completion of the sale, the director directly owned 73,743 shares of the company's stock, valued at approximately $4,348,624.71. This trade represents a 58.74% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 188,406 shares of company stock worth $12,019,683 in the last ninety days. Company insiders own 23.49% of the company's stock.
Oruka Therapeutics Price Performance
Shares of NASDAQ:ORKA opened at $98.82 on Friday. Oruka Therapeutics, Inc. has a 1 year low of $12.84 and a 1 year high of $100.34. The company has a market capitalization of $5.96 billion, a PE ratio of -50.94 and a beta of -0.34. The business has a fifty day moving average price of $82.59 and a two-hundred day moving average price of $60.06.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.04. Sell-side analysts anticipate that Oruka Therapeutics, Inc. will post -2.06 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on ORKA. Leerink Partners set a $120.00 price objective on shares of Oruka Therapeutics in a research note on Thursday, April 30th. BTIG Research restated a "buy" rating and issued a $151.00 target price on shares of Oruka Therapeutics in a report on Monday, July 13th. Weiss Ratings raised shares of Oruka Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, July 15th. HC Wainwright reissued a "buy" rating and set a $120.00 price objective on shares of Oruka Therapeutics in a report on Monday, August 3rd. Finally, Piper Sandler restated an "overweight" rating and issued a $180.00 target price on shares of Oruka Therapeutics in a report on Tuesday, June 2nd. Ten analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Oruka Therapeutics presently has an average rating of "Moderate Buy" and an average target price of $134.30.
Get Our Latest Stock Report on Oruka Therapeutics
Oruka Therapeutics Company Profile
(
Free Report)
Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”
The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
